Movement Alert｜PHARMARON Rises 3.49% in Regular Trading, CXO Sector Rallies Ahead of Interim Results Review

Market Focus08-10

On August 10, PHARMARON rose 3.49% in regular trading, trading at HK$28.6/share, with turnover of HK$213 million.

On the news front, the company's board will convene on August 20 to review and approve its first-half interim results. PHARMARON previously guided H1 revenue of RMB 7.47-7.67 billion, representing 16%-19% year-over-year growth, with net profit increasing 4%-10%. Notably, newly signed orders grew over 30%, with small-molecule CDMO orders surging more than 50%.

The broader CXO sector continued to strengthen, with industry leader WuXi AppTec reporting H1 revenue growth of 38.93% and net profit growth of 29.43%, reinforcing the sector's improving fundamentals. On the same day, WuXi AppTec gained 5.46%, WuXi Biologics rose 5.67%, and GenScript Biotech climbed 5.4%, reflecting broad-based sector momentum driven by strong order pipelines and accelerating earnings delivery across the pharmaceutical outsourcing space.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182607382?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 09:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182607382","market":"us","top_or_hot":-1,"title":"Movement Alert｜PHARMARON Rises 3.49% in Regular Trading, CXO Sector Rallies Ahead of Interim Results Review","media":"Market Focus","content":"<p><p>On August 10, PHARMARON rose 3.49% in regular trading, trading at HK$28.6/share, with turnover of HK$213 million.</p><p>On the news front, the company's board will convene on August 20 to review and approve its first-half interim results. PHARMARON previously guided H1 revenue of RMB 7.47-7.67 billion, representing 16%-19% year-over-year growth, with net profit increasing 4%-10%. Notably, newly signed orders grew over 30%, with small-molecule CDMO orders surging more than 50%.</p><p>The broader CXO sector continued to strengthen, with industry leader WuXi AppTec reporting H1 revenue growth of 38.93% and net profit growth of 29.43%, reinforcing the sector's improving fundamentals. On the same day, WuXi AppTec gained 5.46%, WuXi Biologics rose 5.67%, and GenScript Biotech climbed 5.4%, reflecting broad-based sector momentum driven by strong order pipelines and accelerating earnings delivery across the pharmaceutical outsourcing space.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PHARMARON Rises 3.49% in Regular Trading, CXO Sector Rallies Ahead of Interim Results Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PHARMARON Rises 3.49% in Regular Trading, CXO Sector Rallies Ahead of Interim Results Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-10 09:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 10, PHARMARON rose 3.49% in regular trading, trading at HK$28.6/share, with turnover of HK$213 million.</p><p>On the news front, the company's board will convene on August 20 to review and approve its first-half interim results. PHARMARON previously guided H1 revenue of RMB 7.47-7.67 billion, representing 16%-19% year-over-year growth, with net profit increasing 4%-10%. Notably, newly signed orders grew over 30%, with small-molecule CDMO orders surging more than 50%.</p><p>The broader CXO sector continued to strengthen, with industry leader WuXi AppTec reporting H1 revenue growth of 38.93% and net profit growth of 29.43%, reinforcing the sector's improving fundamentals. On the same day, WuXi AppTec gained 5.46%, WuXi Biologics rose 5.67%, and GenScript Biotech climbed 5.4%, reflecting broad-based sector momentum driven by strong order pipelines and accelerating earnings delivery across the pharmaceutical outsourcing space.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1182607382","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182607382","pubTimestamp":1786326797,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 10, PHARMARON rose 3.49% in regular trading, trading at HK$28.6/share, with turnover of HK$213 million.On the news front, the company's board will convene on August 20 to review and approve...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势警报|康龙化成常规交易上涨3.49%，CXO板块在中期业绩审查前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On August 10, PHARMARON rose 3.49% in regular trading, trading at HK$28.6/share, with turnover of HK$213 million.On the news front, the company's board will convene on August 20 to review and approve its first-half interim results. PHARMARON previously guided H1 revenue of RMB 7.47-7.67 billion, representing 16%-19% year-over-year growth, with net profit increasing 4%-10%. Notably, newly signed orders grew over 30%, with small-molecule CDMO orders surging more than 50%.The broader CXO sector continued to strengthen, with industry leader WuXi AppTec reporting H1 revenue growth of 38.93% and net profit growth of 29.43%, reinforcing the sector's improving fundamentals. On the same day, WuXi AppTec gained 5.46%, WuXi Biologics rose 5.67%, and GenScript Biotech climbed 5.4%, reflecting broad-based sector momentum driven by strong order pipelines and accelerating earnings delivery across the pharmaceutical outsourcing space.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182607382","isCrawlerRequest":true}